ࡱ> HG  \p ktzovelekis Ba=  =xKx<$8X@"1RArial1RArial1RArial1RArial1RArial1RVerdana1RArial1 RArial1$RArial3#,##0\ " ";\-#,##0\ " "=#,##0\ " ";[Red]\-#,##0\ " "?#,##0.00\ " ";\-#,##0.00\ " "I"#,##0.00\ " ";[Red]\-#,##0.00\ " "q*6_-* #,##0\ " "_-;\-* #,##0\ " "_-;_-* "-"\ " "_-;_-@_-k)3_-* #,##0\ _ _-;\-* #,##0\ _ _-;_-* "-"\ _ _-;_-@_-,>_-* #,##0.00\ " "_-;\-* #,##0.00\ " "_-;_-* "-"??\ " "_-;_-@_-{+;_-* #,##0.00\ _ _-;\-* #,##0.00\ _ _-;_-* "-"??\ _ _-;_-@_-"$"#,##0_);\("$"#,##0\)!"$"#,##0_);[Red]\("$"#,##0\)""$"#,##0.00_);\("$"#,##0.00\)'""$"#,##0.00_);[Red]\("$"#,##0.00\)72_("$"* #,##0_);_("$"* \(#,##0\);_("$"* "-"_);_(@_).)_(* #,##0_);_(* \(#,##0\);_(* "-"_);_(@_)?:_("$"* #,##0.00_);_("$"* \(#,##0.00\);_("$"* "-"??_);_(@_)61_(* #,##0.00_);_(* \(#,##0.00\);_(* "-"??_);_(@_)![$-408]dddd\,\ d\ mmmm\ yyyy                + ) , *      "x@ @  "X    p Q  ` #DDrugDevelopmentMarch2008 nJDrugDevelopmentApril2008TDrugDevelopmentMay08\DrugDevelopmentJune08dDrugDevelopmentJuly08" rPDateURLTitleSummarySource Bioportfolio3BioInvent Interim Report: 1 January - 31 March 2008 BioInventEAll study subjects have been dosed in the initial Phase I programme with product candidate TB-403 for treatment of cancer. Two drug interaction studies are ongoing and proceed as planned with the drug TB-402 for the prevention of blood clots. Results from these studies are expected to be available during the second quarter.9http://www.bioportfolio.com/biotech_news/BioInvent_26.htm 25/3/2008]OXFORD BIOMEDICA REPORT ENCOURAGING NEW PHASE II TRIAL RESULTS WITH TROVAX IN PROSTATE CANCEROxford BioMedica (LSE: OXB), a leading gene therapy company, today announces encouraging new data from its first Phase II trial of TroVax in prostate cancer. TroVax is Oxford BioMedica s lead cancer immunotherapy product, which is being developed in collaboration with sanofi-aventis. @http://www.bioportfolio.com/biotech_news/Oxford_BioMedica_54.htmDAmgen and Lab21 in Partnership Agreement for New Cancer Therapy TestUnder the terms of the agreement, leading diagnostics company Lab21 will provide a screening test to indicate which patients are likely to benefit from Amgen s new drug for advanced bowel cancer Vectibix (panitumumab). It is the first time that the European Commission has licensed a bowel cancer product with the stipulation that a predictive test should be carried out. The Lab 21 test was developed by DxS Ltd, a developer of biomarker assays and companion diagnostics for targeted cancer therapies. 17/3/20085http://www.bioportfolio.com/biotech_news/Lab21_11.htmPolyplus-transfection Unveils a New Technology that Improves Intracellular Delivery of Small Interfering RNAs in vivo and Opens the Way to New Therapeutic Possibilities Polyplus-transfection, a company specialized in research, development and commercialization of innovative reagents for delivery of biomolecules, today announces the development of a new technology that improves in vivo delivery of small interfering RNAs (siRNAs) when they are associated with a cationic polymer. This technology is based on a new class of small interfering RNAs the company has developed: "sticky siRNAs" (ssiRNAs). 24/4/2208Dhttp://www.bioportfolio.com/biotech_news/Polyplus-transfection_3.htmSAffitech to help new Norwegian Cancer Stem Cell Center speed up biomarker discovery%Affitech AS, the Norwegian human antibody therapeutics company, announced today its membership in the newly inaugurated Norwegian Center for Stem Cell Based Tumor Therapy (CAST). In the frame of this participation, Affitech will use its proprietary CBAS"! (Cell Based Antibody Selection) platform to identify molecules of clinical interest. CBAS"! is a reverse screening approach which utilizes both patient-derived and nave antibody libraries to rapidly generate fully human antibodies and their cognate antigens when present in their natural setup. 15/4/22087http://www.bioportfolio.com/biotech_news/Affitech_2.htm;PepTcell starts safety studies for novel T-cell HIV vaccinePepTcell Ltd. an immunology company with a focus on the development of vaccines for the prevention and treatment of infectious diseases, has started safety studies for its novel HIV-v vaccine, a vaccine which in addition to stopping HIV infection, could also be used for treating HIV. 7http://www.bioportfolio.com/biotech_news/PepTcell_3.htmsCyclacel Pharmaceuticals announces multiple presentations at American Association of Cancer Research Annual MeetingCyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) announced today the presentation of eight posters highlighting preclinical data of Cyclacel s cell cycle inhibitors, sapacitabine, seliciclib and CYC116, at the upcoming American Association of Cancer Research (AACR) Annual Meeting. The meeting is being held in the San Diego Convention Center in San Diego, CA from April 12 - 16, 2008. Ghttp://www.bioportfolio.com/biotech_news/Cyclacel_Pharmaceuticals_9.htm`CYCLACEL PHARMACEUTICALS PRESENTS INSIGHTS INTO THE MECHANISMS OF ITS CELL CYCLE INHIBITOR DRUGS 16/4/2208OCyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) and independent investigators presented eight posters at the annual meeting of the American Association for Cancer Research (AACR) with preclinical data demonstrating the ability of Cyclacel s cell cycle inhibitors to induce cancer cell death, or apoptosis, by inhibiting key enzymes. Five of these preclinical studies evaluated Cyclacel s CYC116 cell cycle inhibitor. The studies provide additional evidence that CYC116 inhibits Aurora kinases and Vascular Endothelial Growth Factor Receptor-2 tyrosine kinase or VEGFR-2 kinase. Hhttp://www.bioportfolio.com/biotech_news/Cyclacel_Pharmaceuticals_10.htm}Neurodegenerative disease specialist enrolls European Phase II of lead molecule in patients with Nonalcoholic SteatohepatitisTrophos SA, a biopharmaceutical company specializing in the discovery and development of drugs for neurological disorders, announced today that the first patients with NonAlcoholic SteatoHepatitis (NASH) have been enrolled in an exploratory Phase IIa clinical trial of its lead product, TRO19622. It is the first study investigating the potential benefits of TRO19622 beyond neurological conditions. 15/5/20087http://www.bioportfolio.com/biotech_news/Trophos_12.htmAffimed validates antibody target for cancer metastasis - Results published in current issue of the Journal of Molecular BiologyxAffimed Therapeutics AG, a biopharmaceutical company focused on the development of antibody therapeutics, announced today that a collaboration with Dr. Stefan Weiss at the Institute of Biochemistry of the Ludwig Maximilian University in Munich has strongly validated a target for cancer metastases amenable to the development of antibodies or other therapeutic< interventions. 13/5/20086http://www.bioportfolio.com/biotech_news/Affimed_5.htmcPharmaceutical Profiles helps break the habit of ineffective early drug development decision makingThroughout May, Pharmaceutical Profiles (Ruddington, UK) is maintaining its focus on innovative clinical and pre-clinical protocols that support effective and efficient drug development. The company s latest webinar and workshop schedule includes events that address important issues, including: gaining an early understanding of bioavailability, optimizing formulation strategy for efficient development, and testing the feasibility of controlled release delivery. Ghttp://www.bioportfolio.com/biotech_news/Pharmaceutical_Profiles_11.htmuPromising In Vivo Data for VAL 101 Compound - targets Pancreatic Cancer, based on GeneICE"! Gene Silencing Technology 26/6/2008ValiRx plc (AIM:VAL,  ValiRx ), the cancer therapeutics and diagnostics company, has announced promising in vivo results for its lead molecule VAL 101 which uses its gene silencing technology GeneICE"! in preclinical xenograph models of pancreatic cancer. 5http://www.bioportfolio.com/biotech_news/ValiRx_1.htmmBioInvent and ThromboGenics announce a strategic alliance with Roche for TB-403, a novel anti-cancer antibodyBioInvent International AB (OMX Nordic Exchange Stockholm: BINV) and ThromboGenics NV (Euronext Brussels: THR) announce that they have entered into a license agreement with Roche (SWX: ROG) for their jointly developed anti-cancer agent TB-403. TB-403 is a novel monoclonal antibody which blocks Placental Growth Factor (PIGF), one of the growth factors responsible for the development of new blood vessels. 18/6/20089http://www.bioportfolio.com/biotech_news/BioInvent_28.htmCCobrabio Announces Manufacturing Agreement with ViroMed for VM206RYCobra Biomanufacturing Plc (AIM: CBF), the international manufacturer of biopharmaceuticals, today announces that it has signed an agreement with ViroMed Co., Ltd. in Korea to produce VM206RY, a plasmid DNA treatment for tumours expressing Her2/neu (breast, ovarian, pancreatic, and stomach cancers). Under the agreement, Cobrabio will produce ViroMed s Master Cell Bank and GMP-grade VM206RY for clinical trials which will be held in Korea and in the United States.Fhttp://www.bioportfolio.com/biotech_news/Cobra_Biomanufacturing_27.htmcBioInvent and ThromboGenics report positive Phase I results for anti-PlGF cancer therapeutic TB-403iBioInvent International AB (OMX Nordic Exchange Stockholm: BINV) and co-development partner ThromboGenics NV (Euronext Brussels: THR) today reported that the results from the first Phase l study of novel anti-cancer agent TB-403 showed that it is safe and well tolerated, with pharmacokinetic properties enabling it to be developed for the treatment of cancer. 9http://www.bioportfolio.com/biotech_news/BioInvent_27.htmnInfinity Initiates Clinical Development of IPI-493, Its Oral Anti-Chaperone Agent, in Patients With Advanced STradingMarkets 30/7/2008>http://www.tradingmarkets.com/.site/news/Stock%20News/1792372/[Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced that it has initiated a Phase 1 clinical trial of IPI-493, its oral anti-chaperone agent, in patients with advanced solid tumors. IPI-493 has demonstrated significant oral availability, as well as potent and selective inhibition of heat shock protein 90 (Hsp90), in preclinical studies.cLorus Therapeutics Announces Allowance of New United States Patent for its Anticancer Drug LOR-2040('Lorus'), a biopharmaceutical company specializing in the research and development of pharmaceutical products and technologies for the management of cancer, today announced the allowance& ;http://c.moreover.com/click/here.pl?z1531375962&z=950242273mPolyphenon Pharma Receives Orphan Drug Designation for Its Botanical Drug, Polyphenon E, for the Treatment of 29/7/2008Pharmalive.comPolyphenon Pharma, an emerging research-based pharmaceutical company, today announced that the Food and Drug Administration (FDA) has granted Orphan Drug Designation to its botanical drug, Polyphenon E, for the treatment of chronic lymphocytic leukemia (CLL).?http://salesandmarketingnetwork.com/news_release.php?ID=2025508$Healthcare Sales & Marketing NetworknPhase II Data on Lilly's Antibody Show It Affects Amyloid Beta, a Protein Believed To Be Associated with AlzhePolyphenon Pharma, an emerging research-based pharmaceutical company, today announced that the Food and Drug Administration (FDA) has granted Orphan Drug Designation to its botanical drug,& 28/7/2008Portland Business Journal;http://c.moreover.com/click/here.pl?z1532867502&z=950242273R - = (6905z ;?Qcc   DF  dMbP?_*+%"??htU} m} } } } m      ~ @C@              h<FFF>@7 yK :http://www.bioportfolio.com/biotech_news/BioInvent_26.htmyK thttp://www.bioportfolio.com/biotech_news/BioInvent_26.htm<yK Ahttp://www.bioportfolio.com/biotech_news/Oxford_BioMedica_54.htmyK http://www.bioportfolio.com/biotech_news/Oxford_BioMedica_54.htmyK 6http://www.bioportfolio.com/biotech_news/Lab21_11.htmyK lhttp://www.bioportfolio.com/biotech_news/Lab21_11.htm    *K&N  dMbP?_*+%"F??6U} $ F} $ F                   ~ @    ~ @     !  " #   FFFFFF >@7LyK Ehttp://www.bioportfolio.com/biotech_news/Polyplus-transfection_3.htmyK http://www.bioportfolio.com/biotech_news/Polyplus-transfection_3.htmyK 8http://www.bioportfolio.com/biotech_news/Affitech_2.htmyK phttp://www.bioportfolio.com/biotech_news/Affitech_2.htmyK 8http://www.bioportfolio.com/biotech_news/PepTcell_3.htmyK phttp://www.bioportfolio.com/biotech_news/PepTcell_3.htmXyK Hhttp://www.bioportfolio.com/biotech_news/Cyclacel_Pharmaceuticals_9.htmyK http://www.bioportfolio.com/biotech_news/Cyclacel_Pharmaceuticals_9.htm\yK Ihttp://www.bioportfolio.com/biotech_news/Cyclacel_Pharmaceuticals_10.htmyK http://www.bioportfolio.com/biotech_news/Cyclacel_Pharmaceuticals_10.htm    {UX  dMbP?_*+%"F??IU} $ F} $ F         $ &  % ' ( *  ) + ,~ b@  - .     hFFFF >@7yK 8http://www.bioportfolio.com/biotech_news/Trophos_12.htmyK phttp://www.bioportfolio.com/biotech_news/Trophos_12.htmyK 7http://www.bioportfolio.com/biotech_news/Affimed_5.htmyK nhttp://www.bioportfolio.com/biotech_news/Affimed_5.htmXyK Hhttp://www.bioportfolio.com/biotech_news/Pharmaceutical_Profiles_11.htmyK http://www.bioportfolio.com/biotech_news/Pharmaceutical_Profiles_11.htm    \_  dMbP?_*+%"F??HU} $ F} $ F @@@@@@@@ @ @      / 0  1 2 3 5  4 6 7~  b@  8 9 :~  K@  ; <    FFFFF >@  7yK 6http://www.bioportfolio.com/biotech_news/ValiRx_1.htmyK lhttp://www.bioportfolio.com/biotech_news/ValiRx_1.htm yK :http://www.bioportfolio.com/biotech_news/BioInvent_28.htmyK thttp://www.bioportfolio.com/biotech_news/BioInvent_28.htmTyK Ghttp://www.bioportfolio.com/biotech_news/Cobra_Biomanufacturing_27.htmyK http://www.bioportfolio.com/biotech_news/Cobra_Biomanufacturing_27.htm yK :http://www.bioportfolio.com/biotech_news/BioInvent_27.htmyK thttp://www.bioportfolio.com/biotech_news/BioInvent_27.htm    Oeh  dMbP?_*+%"F??:U} $ F} $ F         = ? > A @ B ? G C D E F J H I K M N L O    FFFFF >@70yK ?http://www.tradingmarkets.com/.site/news/Stock%20News/1792372/yK zhttp://www.tradingmarkets.com/.site/news/Stock News/1792372/(yK <http://c.moreover.com/click/here.pl?z1531375962&z=950242273yK xhttp://c.moreover.com/click/here.pl?z1531375962&z=9502422738yK @http://salesandmarketingnetwork.com/news_release.php?ID=2025508yK http://salesandmarketingnetwork.com/news_release.php?ID=2025508(yK <http://c.moreover.com/click/here.pl?z1532867502&z=950242273yK xhttp://c.moreover.com/click/here.pl?z1532867502&z=950242273 Oh+'0l08 L Xd ktzovelekis@cZ@l՜.+,D՜.+,p,HP X`hp x ' DrugDevelopmentMarch2008DrugDevelopmentApril2008DrugDevelopmentMay08DrugDevelopmentJune08DrugDevelopmentJuly08  Worksheets\  8@ _PID_HLINKSA r366http://www.bioportfolio.com/biotech_news/Lab21_11.htm+Ahttp://www.bioportfolio.com/biotech_news/Oxford_BioMedica_54.htmx:http://www.bioportfolio.com/biotech_news/BioInvent_26.htm6Ihttp://www.bioportfolio.com/biotech_news/Cyclacel_Pharmaceuticals_10.htm<YHhttp://www.bioportfolio.com/biotech_news/Cyclacel_Pharmaceuticals_9.htm%h8http://www.bioportfolio.com/biotech_news/PepTcell_3.htm>w8http://www.bioportfolio.com/biotech_news/Affitech_2.htmr~Ehttp://www.bioportfolio.com/biotech_news/Polyplus-transfection_3.htm?Hhttp://www.bioportfolio.com/biotech_news/Pharmaceutical_Profiles_11.htm \7http://www.bioportfolio.com/biotech_news/Affimed_5.htm 8http://www.bioportfolio.com/biotech_news/Trophos_12.htm~x:http://www.bioportfolio.com/biotech_news/BioInvent_27.htmXGhttp://www.bioportfolio.com/biotech_news/Cobra_Biomanufacturing_27.htmqx:http://www.bioportfolio.com/biotech_news/BioInvent_28.htmO6http://www.bioportfolio.com/biotech_news/ValiRx_1.htm'x<http://c.moreover.com/click/here.pl?z1532867502&z=950242273>@http://salesandmarketingnetwork.com/news_release.php?ID=2025508)w<http://c.moreover.com/click/here.pl?z1531375962&z=950242273B=http://www.tradingmarkets.com/.site/news/Stock News/1792372/  !"#$%&'()*+,-./012345689:;<=>@ABCDEFRoot Entry FWorkbook:mSummaryInformation(7DocumentSummaryInformation8?